



HOKKAIDO UNIVERSITY

Title	2-(p-Nitrophenyl)-2' -deoxyadenosine, a new type of mutagenic nucleoside
Author(s)	Matsuda, Akira; Ohara, Yoshiko; Kakutani, Toshifumi et al.
Citation	Nucleic Acids Research, 18(7), 1833-1838 https://doi.org/10.1093/nar/18.7.1833
Issue Date	1990-04
Doc URL	https://hdl.handle.net/2115/46969
Type	journal article
File Information	73_90 NAR 2-N02Ph-dAdo.pdf



2-(*p*-Nitrophenyl)-2'-deoxyadenosine, a new type of mutagenic nucleoside

Akira Matsuda*, Yoshiko Ohara¹, Toshifumi Kakutani¹, Kazuo Negishi¹, Yusuke Wataya¹, Hikoya Hayatsu¹ and Tohru Ueda

Faculty of Pharmaceutical Sciences, Hokkaido University, Kita-12, Nishi-6, Kita-ku, Sapporo 060 and

¹Faculty of Pharmaceutical Sciences, Okayama University, Tsushimanaka 1-1-1, Okayama 700, Japan

Received November 28, 1989, Revised and Accepted January 4, 1990

ABSTRACT

A crude preparation of 2-phenyladenosine was found to be mutagenic in the Ames *Salmonella* assay. In the purification of this preparation, it was revealed that 2-phenyladenosine itself was nonmutagenic but that 2-(*m*- and *p*-nitrophenyl)-adenosines (5*m*,*p*) contaminating the sample were the mutagenic principles. A structure-activity relationship study was carried out, and it was found that 5*p*, 2-(*p*-nitrophenyl)-adenine (7*p*), and 2-(*p*-nitrophenyl)-2'-deoxyadenosine (15*p*) were strongly mutagenic toward *S. typhimurium* TA98 and TA100 without metabolic activation, the potency being in the order 15*p* > 7*p* > 5*p*. The potency of 15*p* in TA98 was one order of magnitude greater than that of 4-nitroquinoline N-oxide. 15*p* also showed mutagenicity in the mouse cell line FM3A in culture.


INTRODUCTION

Some nucleosides such as 5-bromodeoxyuridine², N⁴-hydroxycytidine³⁻⁵, and N⁴-aminocytidine⁶, and nucleobases such as 2-aminopurine² and 2-amino-6-hydroxyaminopurine⁷ have been known to be mutagenic. Most of these compounds act actually as promutagens. By cellular metabolism, these compounds are converted into corresponding 2'-deoxynucleoside 5'-triphosphates, which would be incorporated into DNA chains during replication and induce mutations. Elucidation of the mechanism of these phenomena is important for understanding mutagenesis and even carcinogenesis.

We have tested about 100 modified nucleosides for mutagenicity by the reversion of histidine dependent *Salmonella* system (*Salmonella typhimurium* TA98 for detection of mutagens causing frameshifts and TA100 for those causing base-pair changes)⁸ in the absence or presence of rat-liver 9000×g supernatant fraction (S9). Among these nucleoside derivatives, we have found a crude preparation of 2-phenyladenosine (3) to be mutagenic to TA98 as well as TA100 without metabolic activation by S9. This nucleoside was synthesized⁹ by the route shown in scheme 1. 2-Amino-6-chloropurine riboside (1) was treated with an excess of isopentyl nitrite in benzene in the

presence of copper(I) oxide to afford a 6-chloro-2-phenylpurine riboside (2). The crude product of 2 was then heated with methanolic ammonia in a sealed tube at 70° to give a crude 3. We describe here the structure determination of the minor mutagenic products in this sample and the results of studies on the structure-activity relationship of the mutagenicity. Preliminary accounts of this work have appeared^{10,11}.

Scheme 1



RESULTS and DISCUSSION

In order to determine the chemical structure of the mutagenic compounds, the crude sample was purified with high performance liquid chromatography (HPLC) using a reverse phase column (Fig.1). The purified 2-phenyladenosine (3; peak 1) showed no mutagenicity in TA98 and TA100. Instead, the mutagenic activity toward both strains was almost entirely concentrated in one of the minor peaks (peak 3), which seemed to consist of more than one compound. From about 200 mg of crude 3, 0.8 mg of a mixture of the minor nucleosides was isolated by using a semi-preparative column. The ¹H-NMR spectra of this sample from peak 3 showed that the mixture consisted of at least two components and the phenyl ring at the 2-position of adenine moiety was mono-substituted (Fig.2). Mass spectral data of this material showed a molecular ion peak at *m/z* 388; the number corresponding to the molecular weight of 2-phenyladenosine minus 1 plus NO₂ (46). From these results, the compounds of peak 3 appeared to be a mixture of isomeric 2-(nitrophenyl)-adenosines.

To determine the position of the nitro group in the phenyl ring, we synthesized 2-(*o*-, *m*- and *p*-nitrophenyl)-adenosines (5*o*,*m*,*p*) in an unambiguous manner¹². Treatment of 4-cyano-5-aminoimidazole riboside (4)¹¹, which was obtained

* To whom correspondence should be addressed





Figure 1. HPLC chromatogram of the crude sample of 3. Retention times of peak 1, 2, 3, and 4 were 8.2, 11.3, 14.3, and 27.1 min, respectively.

readily from commercially available 5-aminoimidazole-4-carboxamide riboside in two steps, with *o*-, *m*-, or *p*-nitrobenzonitriles in methanolic ammonia using a steel tube at 170°, afforded desired 2-(*o*-, *m*-, or *p*-nitrophenyl)-adenosines (**5o**, **5m**, and **5p**) in yields of 20, 51, and 71%, respectively (Scheme 2). The 2-(*m*- and *p*-nitrophenyl)-adenosines (**5m** and **5p**) showed retention times (13.7 and 14.0 min, respectively) almost the same as that of peak 3 (14.3 min). The retention time of 2-(*o*-nitrophenyl)-adenosine (**5o**) was found to be very short (4.7 min). ¹H-NMR spectral data (the aromatic region) of peak 3 and other derivatives are shown in Fig.2 and it is evident that peak 3 contains **5m** and **5p** in a ratio of 1:3.

Scheme 2



We next examined the mutagenic activity of these nucleosides. Both **5m** and **5p** showed mutagenic activity with either TA98 and TA100 strains dose-dependently with or without addition of S9 (Fig.3). It is interesting to note that the *m*-nitro analog (**5m**) is selectively active to TA100. In contrast, the *p*-nitro derivative (**5p**) showed potent mutagenicity to TA98 and at higher concentrations, cell killing occurred with TA100. On the other hand, the *o*-nitro derivative (**5o**) showed no activity to either




Figure 2. 270 MHz ¹H-NMR spectrum of peak 3, **5o**, **5m**, and **5p** in DMSO-d₆.


strains. From these results, it is clear that during the diazotization of 1 in benzene with isopentyl nitrite, the intermediate(s) was nitrated to produce 2-(*m*- and *p*-nitrophenyl)-adenosines as minor components, which caused the mutagenicity from crude 3.

Some aromatic nitro compounds are mutagenic. For example, 4-nitroquinoline N-oxide and dinitropyrenes have been shown to have potent mutagenicity and carcinogenicity. Nitropyrene and dinitropyrenes especially are known to be common mutagenic environmental contaminants. Thus, it is interesting to study whether the mutagenicity of 5m and 5p arises from the nucleosidic character or whether they are behaving just as aromatic nitro compounds.

To clarify further the structural requirements for the mutagenicity, several nucleoside and base analogs were prepared. 2-(*p*-Nitrophenyl)-adenosine (5p) was deaminated with sodium nitrite in aqueous acetic acid at room temperature for 4 days to give the inosine derivative (8) in 71% yield. The nitro group in compound 5p was reduced by catalytic hydrogenation with 10% palladium on carbon, and the anilino adenosine (6) was obtained in 50% yield. Nucleosides 5m, 5p, and 8 were treated with 2N hydrochloric acid to afford the corresponding 2-(*m*- and *p*-nitrophenyl)-adenines (7m and 7p) and 2-(nitrophenyl)-hypoxanthine (9) (Scheme 3). As sugar analogs of 5m and 5p, 2-(*m*- and *p*-nitrophenyl)-2'-deoxyadenosines (15m and 15p) were next synthesized. 5-Amino-4-cyanoimidazole riboside (10) was treated with 1,3-dichloro-1,1,3,3-tetraisopropylidisiloxane (TIPDS) in *N,N*-dimethylformamide (DMF) to give the corresponding 3',5',*O*-tetraisopropylidisiloxanyl (TIPDS) derivative (11) in 74% yield after purification over a silica gel column¹³. Compound 11 was then treated with *N,N*-thiocarbonyldiimidazole in DMF to afford the 2'-thiocarbonyl derivative (12) in a crystalline form (72% yield). 12 was subjected to radical-deoxygenation with tributyltin hydride¹⁴ in toluene, giving the desired 2'-deoxynucleoside (13) exclusively. Compound 13 was then cyclized with *m*- and *p*-nitrobenzonitriles in ethanolic ammonia to afford the 2-(*m*- and *p*-nitrophenyl)-deoxyadenosine derivatives (14m and 14p) in 48% and 84% yield, respectively. The nucleosides were deblocked with tetrabutylammonium fluoride in tetrahydrofuran to furnish 2-(*m*- and *p*-nitrophenyl)-2'-deoxyadenosines (15m and 15p), respectively, in good yields. In contrast, when the same radical deoxygenation was applied to the 2'-thiocarbonyl-2-(*p*-nitrophenyl)-adenosine derivative, only a complex mixture was obtained (data not shown).

The mutagenicity of the nucleosides and bases toward *S. typhimurium* TA98 and TA100 in the absence or presence of S9 is summarized in Table 1. Data for known mutagens, N⁴-aminocytidine, 4-nitroquinoline N-oxide (4NQO) and benzo[*a*]pyrene (BP), are also shown for comparison. Among

Scheme 3



Scheme 4





Figure 3. Mutagenicity of 5p (A) and 5m (B) on *S. typhimurium* TA98 and TA100. Circle symbols, TA100; triangle symbols, TA98. Solid symbols, +S9; open symbols, -S9.

Table 1. Mutagenicity of 2-(nitrophenyl)-adenines on *S. typhimurium*^a

Bacteria Comps	TA98		TA100	
	+S9	-S9	+S9	-S9
5p	820	1700	940	870
5m	4	7	51	680
5o	0	0	0	0
6	79	24	0	8
8	193	546	224	575
7p	1000	30000	1100	40000
7m	0	0	100	900
9	40	1000	0	1300
15p	67000	117000	16000	42000
15m	58	200	180	200
N ⁴ -aminocytidine	0	0	3400	1300
4NQO	0	18000	0	80000
BP	1200	0	2400	0

^aNet number of revertants/10 µg of compound per plate

the *p*-, *m*-, or *o*-nitrophenyladenosine derivatives (5p,m,o), the *p*-nitrophenyl derivative (5p) is the most potent. The *m*-nitrophenyl derivative (5m) is active only to TA100 without metabolic activation. On the other hand, *o*-nitrophenyl derivative (5o) is inactive with either strains. The *o*-nitrophenyl ring cannot be coplanar with the adenine ring because of steric repulsion between the *o*-nitro group and the pyrimidine moiety of adenine ring. This is probably one reason why 5o did not show mutagenic activity. The anilino derivative (6) is almost inactive. The inosine analog 8 shows weaker activity than the corresponding adenosine analog 5p. 2-(*p*-Nitrophenyl)-adenine (7p) is found to be much more potent than the nucleoside, whereas the 2-(*m*-nitrophenyl)-adenine (7m) is less mutagenic but selective toward TA100. Again, the hypoxanthine derivative (9) is, as expected, less potent than the adenine derivative. Surprisingly, 2-(*p*-nitrophenyl)-2'-deoxyadenosine (15p) is the most potent among 2-nitrophenyladenines in the reversion of TA98 and TA100, and the activity toward TA98 is one order of magnitude greater than that of 4-nitroquinoline N-oxide. Consistent with the weak mutagenicity of 5m, 15m shows only weak activity. These data indicate that the *p*-nitrophenyl analog is the most potent and the adenine analogs are always more active than the hypoxanthine analogs. The order of mutagenicity is the 2'-deoxynucleosides, the bases and the ribonucleosides.

It is important to elucidate the role of the nitro group for the mutagenicity. When 5p was tested towards nitroreductase deficient strains (TA98/1,8-DNP and TA98NR), none of the strains (without addition of S9) showed significant number of his⁺ revertants (82 and 54 revertants at the concentration of 20 µg/plates, respectively) while TA98 gave 2200 revertants under the same conditions. Compound 7p (1 µg/plate) showed a low activity to TA100/1,8-DNP (570 revertants) and TA100NR (160 revertants) while TA100 gave 3230 revertants. Although 15p did not show any activity toward TA100/1,8 DNP and TA100NR at 0.5 µg/plate. TA100 formed 1550 revertants. Thus, it is obvious that the nitro group is essential for the mutagenicity.

The mutagenic activity of 15p to FM3A cells was also investigated by measuring mutations to ouabain resistance. As shown in Table 2, 15p exhibited mutagenicity with a potency close to that of N⁴-aminocytidine¹⁵. Since EC₅₀ of 15p for FM3A cells was 3.2×10⁻⁵ M, this reagent showed no cytotoxicity at the concentrations tested for the mutagenicity.

From these studies, one can speculate that 2-(*p*-nitrophenyl)-adenine (7p) and the 2'-deoxy analog (15p), like other nitro aromatic compounds, would be reduced to the hydroxylamino

Table 2. Mutation assay in FM3A cells

Concentration [M]	No. of ouabain resistant mutants scored/total No. of original cells	Mutation frequency (oua ^r ⇒ oua ^s) ^a	Colony-forming ability (%) ± S.D (n=15)
2-(<i>p</i> -Nitrophenyl)-2'-deoxyadenosine (15p)			
Control:0	0/1.5×10 ⁷	0	84.9 ± 9.8
5.4×10 ⁻⁶	31/1.4×10 ⁷	2.5×10 ⁻⁶	90.3 ± 8.8
1.0×10 ⁻⁵	68/1.5×10 ⁷	5.3×10 ⁻⁶	85.1 ± 12.4
N ⁴ -Aminocytidine ^b			
3.0×10 ⁻⁵	87/9.5×10 ⁶	1.1×10 ⁻⁵	86

^a(Number of mutants) / (number of original cells×colony-forming ability)^bData taken from ref. 15.

derivatives by the action of nitroreductase, and that these activated bases would react with DNA to form adducts. Also, the hydroxylamino derivatives may be further activated by acylation and/or sulfation for the reaction with DNA. On the other hand, in the case of the 2'-deoxy compound (15p), it might be phosphorylated and incorporated into DNA after or before activation of the nitro group. The detailed mechanism of the mutagenic action of these compounds is a subject of further studies.

EXPERIMENTAL

Melting points were determined on a Yanagimoto MP-3 micromelting point apparatus and are uncorrected. The ¹H-NMR spectra were recorded on a JEOL FT100FT or FX-270FT spectrometer with tetramethylsilane as an internal standard. Chemical shifts are reported in parts per million (δ), and signals are expressed as s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), or br (broad). All exchangeable protons were detected by addition of D₂O. UV absorption spectra were recorded with a Shimadzu UV-240 spectrophotometer. Electron impact mass spectra (Mass) were measured on a JEOL D-300 spectrometer. TLC was performed on Merck Kieselgel F254 precoated plates. Silica gel used for column chromatography was YMC gel 60A (70–230 mesh). HPLC analyses were performed on a JASCO TRI ROTAR-V system using Shodex ODS pak F-411 (4.6×150 mm) with 40% aqueous methanol as an eluting solvent at a flow rate of 1 ml/min.

2-(*p*-Nitrophenyl)-adenosine (5p). A mixture of 2',3',5'-tri-*O*-acetyl-5-amino-4-cyanoimidazole riboside (4; 2.0 g, 5.5 mmol) and *p*-nitrobenzonitrile (2.0 g, 13.5 mmol) in methanolic ammonia (saturated at 0°C, 30 ml) was heated at 170°C in a sealed steel tube. After 6 h, the tube was cooled to room temperature, opened, and the resulting precipitates were collected by filtration (5p; 1.5 g, 71%). Analytical sample was obtained by recrystallization from aqueous ethanol, mp 252–253°C. Mass *m/z*: 388 (M⁺). ¹H-NMR (DMSO-d₆): δ 3.62 (m, 2H, 5',5''-H), 3.97 (m, 1H, 4'-H), 4.21 (m, 1H, 3'-H), 4.68 (m, 1H, 2'-H), 5.03 (t, 1H, 5'-OH), 5.25 (d, 1H, 2'- or 3'-OH), 5.50 (d, 1H, 3'- or 2'-OH), 6.02 (d, 1H, 1'-H, J_{1,2'} = 5.9 Hz), 7.54 (brs, 2H, 6-NH₂), 8.35 (d, 2H, 2'' and 6'', J_{2'',3''} = J_{5'',6''} = 8.8 Hz), 8.47 (s, 1H, 8-H), 8.58 (d, 2H, 3'' and 5''H). Anal. Calcd for C₁₆H₁₆N₆O₆: C, 49.49; H, 4.15; N, 21.64. Found: C, 49.34; H, 4.09; N, 21.58.

2-(*m*-Nitrophenyl)-adenosine (5m). A mixture of compound 4 (1.0 g, 2.7 mmol) and *m*-nitrobenzonitrile (1.0 g, 6.8 mmol) in methanolic ammonia (30 ml) in a sealed steel tube was heated at 170°C for 8 h. The resulting solution was evaporated to dryness

and the residue was dissolved in methanol. Silica gel was added to the methanol solution, and the mixture was evaporated to dryness. The residue was placed on a silica gel column, which was eluted with chloroform containing 5% ethanol then eluted with chloroform containing 10% ethanol. From the latter fractions, the desired nucleoside was obtained and the residue was crystallized from aqueous ethanol to give **5m** (541 mg, 51%); mp 235–236°C (sintering from 223°C). Mass m/z : 388 (M^+). $^1\text{H-NMR}$ (DMSO- d_6): δ 3.60 (m, 2H, 5', 5''-H), 3.98 (m, 1H, 4'-H), 4.21 (m, 1H, 3'-H), 4.68 (m, 1H, 2'-H), 5.03 (t, 1H, 5'-OH), 5.25 (d, 1H, 2'- or 3'-OH), 5.50 (d, 1H, 3'- or 2'-OH), 6.03 (d, 1H, 1'-H, $J_{1,2'} = 6.3$ Hz), 7.57 (brs, 2H, 6-NH₂), 7.79 (t, 1H, 5''-H, $J_{4'',5''} = 8.1$ Hz), 8.32 (dd, 1H, 6''-H, $J_{4'',6''} = 1.1$ Hz, $J_{5'',6''} = 8.1$ Hz), 8.45 (s, 1H, 8-H), 8.77 (dd, 1H, 4''-H, $J_{2'',4''} = 1.5$ Hz, $J_{4'',5''} = 8.1$ Hz), 9.14 (t, 1H, 2''-H). *Anal.* Calcd for C₁₆H₁₆N₆O₆: C, 49.49; H, 4.15; N, 21.64. Found: C, 49.28; H, 4.30; N, 21.41.

2-(*o*-Nitrophenyl)-adenosine (5o). A mixture of compound **4** (1.0 g, 2.7 mmol) and *o*-nitrobenzonitrile (1.0 g, 6.8 mmol) in methanolic ammonia (30 ml) in a sealed steel tube was heated at 170°C for 8 h. The resulting solution was evaporated to dryness and the residue was dissolved in methanol. Silica gel was added to the methanol solution, and the mixture was evaporated to dryness. The residue was placed on a silica gel column, which was eluted with chloroform containing 5% ethanol then eluted with chloroform containing 10% ethanol. From the latter fractions, the desired nucleoside (**5o**) was obtained as a foam (214 mg, 20%). Mass m/z : 388 (M^+). $^1\text{H-NMR}$ (DMSO- d_6): δ 3.60 (m, 2H, 5', 5''-H), 3.93 (m, 1H, 4'-H), 4.13 (m, 1H, 3'-H), 4.60 (m, 1H, 2'-H), 5.08 (t, 1H, 5'-OH), 5.17 (d, 1H, 2'- or 3'-OH), 5.42 (d, 1H, 3'- or 2'-OH), 5.86 (d, 1H, 1'-H, $J_{1,2'} = 5.9$ Hz), 7.45 (brs, 2H, 6-NH₂), 7.67 (dt, 1H, 4''- or 5''-H, $J_{3'',4''} = J_{4'',5''} = J_{5'',6''} = 7.7$ Hz, $J_{3'',5''} = J_{4'',6''} = 1.5$ Hz), 7.76 (dt, 1H, 5''- or 4''-H), 7.90 (d, 2H, 3''- and 6''-H), 8.42 (s, 1H, 8-H).

2-(*p*-Aminophenyl)-adenosine (6). 10% Palladium on carbon (30 mg) was added to a solution of **5p** (250 mg) in a mixture of ethanol (10 ml) and 50% aqueous acetic acid (20 ml). The mixture was stirred at room temperature under H₂ atmosphere, until a theoretical amount of H₂ was absorbed. The reaction mixture was passed through a celite pad and the eluent was evaporated to dryness. The residue was crystallized from water to give **6** (115 mg, 50%); mp 229–231°C. Mass m/z : 358 (M^+). $^1\text{H-NMR}$ (DMSO- d_6 + D₂O): δ 3.55 (dd, 1H, 5'-H, $J_{4',5'} = 4.0$ Hz, $J_{5',5''} = 11.7$ Hz), 3.67 (dd, 1H, 5''-H, $J_{4',5''} = 4.0$ Hz), 3.93 (dd, 1H, 4'-H), 4.20 (dd, 1H, 3'-H), 4.70 (dd, 1H, 2'-H), 5.94 (d, 1H, 1'-H, $J_{1,2'} = 6.2$ Hz), 6.60 (d, 2H, phenyl, $J = 8.4$ Hz), 8.04 (d, 2H, phenyl, $J = 8.4$ Hz), 8.28 (s, 1H, 8-H). *Anal.* Calcd for C₁₆H₁₈N₆O₄: C, 53.63; H, 5.06; N, 23.45. Found: C, 53.73; H, 5.16; N, 23.16.

2-(*p*-Nitrophenyl)-inosine (8). Sodium nitrite (280 mg, 4.1 mmol) was added to a suspension of **5p** (250 mg, 0.64 mmol) in 50% aqueous acetic acid at 0°C. The reaction mixture was stirred for 4 days at room temperature under a tight sealing. The resulting precipitate was collected by filtration and the solid was crystallized from 50% aqueous ethanol to afford **8** (142 mg, 71%); mp 180–183°C. Mass m/z : 257 ($B+H^+$). $^1\text{H-NMR}$ (DMSO- d_6 + D₂O): δ 3.56 (dd, 1H, 5'-H, $J_{4',5'} = 3.8$ Hz, $J_{5',5''} = 11.5$ Hz), 3.66 (dd, 1H, 5''-H, $J_{4',5''} = 3.8$ Hz), 3.96 (dd, 1H, 4'-H), 4.17 (dd, 1H, 3'-H), 4.57 (dd, 1H, 2'-H), 5.98 (d, 1H, 1'-H, $J_{1,2'} = 6.0$ Hz), 8.37 (m, 4H, phenyl), 8.42 (s, 1H, 8-H). *Anal.* Calcd for C₁₆H₁₅N₅O₇·0.5 H₂O: C, 48.24; H, 4.05; N, 17.58. Found: C, 48.54; H, 3.90; N, 17.45.

2-(*p*-Nitrophenyl)-adenine (7p). A suspension of **5p** (250 mg) in 2N HCl (20 ml) was heated at 60°C for 1 day with stirring. The resulting crystals were collected by filtration (**7p**; 154 mg, 87% as hydrate); mp >300°C. Mass m/z : 256 (M^+). *Anal.* Calcd for C₁₁H₈N₆O₂·H₂O: C, 48.18; H, 3.68; N, 30.64. Found: C, 47.81; H, 3.36; N, 30.34.

2-(*m*-Nitrophenyl)-adenine (7m). A suspension of **5m** (120 mg) in 2N HCl (10 ml) was heated at 60°C for 1 day with stirring. Ethanol (15 ml) was added to the mixture, which was heated until the insoluble materials were dissolved. The resulting solution was filtered and from the filtrate crystalline materials were obtained (**7m**; 75 mg, 95%); mp >300°C. Mass m/z : 256 (M^+). *Anal.* Calcd for C₁₁H₈N₆O₂: C, 51.56; H, 3.15; N, 32.80. Found: C, 51.53; H, 3.08; N, 32.83.

2-(*p*-Nitrophenyl)-hypoxanthine (9). A suspension of **8** (68 mg) in 2N HCl (10 ml) was heated at 60°C for 1 day with stirring. The resulting crystals were collected by filtration to give **9** (36 mg, as a hemihydrate); mp >300°C. Mass m/z : 257 (M^+). *Anal.* Calcd for C₁₁H₇N₅O₃·0.5 H₂O: C, 49.62; H, 3.03; N, 26.31. Found: C, 49.24; H, 3.07; N, 26.01.

5-Amino-1-(3',5'-*O*-TIPDS- β -D-ribofuranosyl)-imidazole-4-carbonitrile (11). TIPDSCl₂ (6.92 g, 1.1 equiv.) was added to a solution of **10** (4.8 g, 20 mmol) in dry pyridine (50 ml) at 0°C. The mixture was stirred for 4.5 h at room temperature. Ice water (ca. 5 ml) was added to the mixture and the mixture was concentrated by evaporation. This residue was coevaporated several times with aqueous ethanol. The residue was dissolved in ethyl acetate (ca. 100 ml) and the mixture was washed with water (20 ml×3). The organic layer was dried (Na₂SO₄) and evaporated to dryness to leave a powder, which was crystallized from hexane to afford **11** (7.25 g, 75%); mp 163–164°C. Mass m/z : 482 (M^+). $^1\text{H-NMR}$ (CDCl₃ + D₂O): δ 1.09 (m, 28H, isopropyl), 4.06 (m, 4H, 3',4',5',5''-H), 5.55 (d, 1H, 1'-H), 7.16 (s, 1H, 2-H). *Anal.* Calcd for C₂₁H₃₈N₄O₅Si₂: C, 52.25; H, 7.93; N, 11.61. Found: C, 52.20; H, 7.94; N, 11.54.

5-Amino-1-(3',5'-*O*-TPIDS-2'-*O*-thiocarbonylimidazolyl- β -D-ribofuranosyl)imidazole-4-carbonitrile (12). A solution of compound **11** (1.45 g, 3 mmol) and *N,N'*-thiocarbonyldiimidazole (90% pure; 1.19 g, 2 equiv.) in dry DMF (15 ml) for 22 h at room temperature. The mixture was diluted with ethyl acetate (100 ml) and was washed with water (20 ml×4). The separated organic phase was dried (Na₂SO₄) and evaporated to dryness. The residue was crystallized from ethanol to give **12** (1.29 g, 72%); mp 219–220°C. Mass m/z : 592 (M^+). $^1\text{H-NMR}$ (CDCl₃): δ 1.11 (m, 28H, isopropyl), 4.13 (m, 3H, 4',5',5''-H), 4.49 (brs, 2H, 5-NH₂), 4.98 (dd, 1H, 3'-H), 5.82 (m, 2H, 1',2'-H), 7.30 (s, 1H, 2-H), 7.10, 7.65, 8.35 (each m, each 1H, imidazole protons). *Anal.* Calcd for C₂₅H₄₀N₆O₅SSi₂: C, 50.65; H, 6.80; N, 14.17. Found: C, 50.37; H, 6.71; N, 14.25.

5-Amino-1-(2'-deoxy-3',5'-*O*-TIPDS- β -D-ribofuranosyl)-imidazole-4-carbonitrile (13). Tributyltin hydride (0.87 ml, 1.5 equiv.) was added to suspension of **12** (1.28 g, 2.16 mmol) and azobisisobutyronitrile (50 mg) in dry toluene (20 ml). The mixture was heated under reflux for 40 min and evaporated to dryness. The residue was purified by a silica gel column which was eluted with chloroform containing 1% ethanol. From this fraction, the desired nucleoside (**13**) was obtained (1.0 g, 99%; crystallized from hexane); mp 95–96°C. Mass m/z : 466 (M^+). $^1\text{H-NMR}$ (CDCl₃): δ 1.06 (m, 28H, isopropyl), 2.52 (m, 2H, 2',2''-H), 3.82 (m, 1H, 4'-H), 3.97 (m, 2H, 5',5''-H), 4.40 (brs, 2H, 5-NH₂), 4.75 (m, 1H, 3'-H), 5.82 (dd, 1H, 1'-H), 7.09 (s, 1H,

2-H). *Anal.* Calcd for $C_{21}H_{38}N_4O_4Si_2$: C, 54.04; H, 8.21; N, 12.00. Found: C, 54.15; H, 8.31; N, 11.86.

2'-Deoxy-3',5'-O-TIPDS-2-(p-nitrophenyl)-adenosine (14p). A mixture of **13** (760 mg, 1.6 mmol) and *p*-nitrobenzonitrile (1.4 g, 9.5 mmol) in ethanolic ammonia (saturated at 0°C, 30 ml) was heated at 170°C for 14 h in a sealed tube. The mixture was evaporated to dryness and the residue was suspended in chloroform. The insoluble material was removed by filtration with a celite pad and the filtrate was evaporated. The residue was crystallized from ethanol to give **14p** (845 mg, 84%); mp 216–218°C. Mass *m/z*: 614 (M^+). 1H -NMR (DMSO- d_6): δ 2.61 (m, 1H, 2'-H), 3.10 (m, 1H, 2''-H), 3.87 (m, 3H, 4',5',5''-H), 4.95 (dd, 1H, 3'-H), 6.42 (dd, 1H, 1'-H, $J_{1',2'} = 2.9$ Hz, $J_{1',2''} = 8.1$ Hz), 7.56 (brs, 2H, 6-NH₂), 8.32 (d, 2H, 3'',5''-H, $J_{2'',3''} = J_{5'',6''} = 8.8$ Hz), 8.33 (s, 1H, 8-H), 8.54 (d, 1H, 2'',6''-H). *Anal.* Calcd for $C_{28}H_{42}N_6O_6Si_2$: C, 54.70; H, 6.89; N, 13.67. Found: C, 54.27; H, 7.01; N, 13.54.

2-Deoxy-2-(p-nitrophenyl)-adenosine (15p). A tetrahydrofuran solution of tetrabutylammonium fluoride (1M, 0.8 ml) was added to a solution of **14p** (221 mg, 0.36 mmol) in dry tetrahydrofuran (10 ml). The mixture was stirred for 30 min at room temperature and then neutralized with acetic acid. The solution was evaporated to dryness and the residue was crystallized from ethanol to afford **15p** (95 mg, 71%); mp >300°C. Mass *m/z*: 372 (M^+). 1H -NMR (DMSO- d_6): δ 2.31–2.38 (m, 1H, 2'-H), 2.77–2.81 (m, 1H, 2''-H), 3.60 (m, 2H, 5',5''-H), 3.90 (m, 1H, 4'-H), 4.47 (m, 1H, 3'-H), 4.94 (t, 1H, 5'-OH), 5.36 (d, 1H, 3'-OH), 6.47 (t, 1H, 1'-H, $J_{1',2'} = 7.0$ Hz), 7.52 (brs, 2H, 6-NH₂), 8.35 (d, 2H, 2'',6''-H, $J_{2'',3''} = J_{5'',6''} = 8.8$ Hz), 8.44 (s, 1H, 8-H), 8.58 (d, 2H, 3'',5''-H). *Anal.* Calcd for $C_{16}H_{16}N_6O_5$: C, 51.61; H, 4.33; N, 22.57. Found: C, 51.60; H, 4.34; N, 22.30.

2'-Deoxy-2-(m-nitrophenyl)-adenosine (15m). A mixture of **13** (200 mg, 0.43 mmol) and *m*-nitrobenzonitrile (400 mg, 2.7 mmol) in ethanolic ammonia (saturated at 0°C, 20 ml) in a sealed tube was heated at 170°C for 7 h. The mixture was evaporated to dryness and the residue was purified over a silica gel column eluted with chloroform containing 1% ethanol to give **14m** (127 mg, 48% as a foam), mass *m/z*: 614 (M^+). Compound **14m** (120 mg, 0.195 mmol) was dissolved in dry tetrahydrofuran (5 ml), which was treated with 1M tetrahydrofuran solution of tetrabutylammonium fluoride (0.5 ml) for 30 min at room temperature. The mixture was neutralized with acetic acid and evaporated to dryness. The residue was crystallized from aqueous methanol to afford **15m** (70 mg, 92% as a hydrate); mp 150–153°C. Mass *m/z*: 372 (M^+). 1H -NMR (DMSO- d_6 + D₂O): δ 2.35 (ddd, 1H, 2'-H, $J_{1',2'} = 6.0$ Hz, $J_{2',3'} = 3.3$ Hz, $J_{2',2''} = 13.2$ Hz), 2.80 (ddd, 1H, 2''-H, $J_{1',2''} = 7.1$ Hz, $J_{2'',3''} = 6.1$ Hz), 3.53 (dd, 1H, 5'-H, $J_{4',5'} = 4.9$ Hz, $J_{5',5''} = 11.5$ Hz), 3.63 (dd, 1H, 5''-H, $J_{4',5''} = 4.9$ Hz), 3.90 (m, 1H, 4'-H), 4.46 (dd, 1H, 3'-H), 6.47 (dd, 1H, 1'-H), 7.79 (t, 1H, 5''-H, $J_{4'',5''} = J_{5'',6''} = 8.2$ Hz), 8.30 (m, 1H, 6''-H), 8.42 (s, 1H, 8-H), 8.76 (d, 1H, 4''-H), 9.13 (t, 1H, 2''-H). *Anal.* Calcd for $C_{16}H_{16}N_6O_5 \cdot H_2O$: C, 49.23; H, 4.65; N, 21.52. Found: C, 49.36; H, 4.57; N, 21.32.

Mutation assay

The Ames assay was performed with the preincubation technique¹⁶. The 9000×g supernatant of liver homogenate (S9) was prepared from rats induced with polychlorinated biphenyl (PCB-54, Tokyo Kasei Chemicals; Cl content, ca. 54%). For metabolic activation, S9 mix containing 50 μ l (per plate) of this S9 and supplementary coenzymes was used. In all the mutation

assays, each datum represents a mean in two plates. For each value, the background revertant score had been subtracted.

Assay for mutagenic activity in FM3A cells

Mouse mammary carcinoma cell line FM3A, subclone F28–7, was maintained at 37°C under 5% CO₂ in suspension culture in ES medium (Nissui Pharmaceutical Co., Ltd., Tokyo) supplemented with 10% heat-inactivated fetal bovine serum (FBS). Mutation to ouabain resistance was measured. Logarithmically growing cells were inoculated into the medium at a density of 5×10^4 cells/ml. The culture was incubated at 37°C for 1 day; then 2-(*p*-nitrophenyl)-2'-deoxyadenosine (**15p**) was added and the cell suspension was incubated for 24 h. The medium was changed, and the cells were cultured for additional 3 days for expression. Then the cells were inoculated into plates of soft-agarose consisting of 0.375% Nobel agar (Difco Laboratories, Detroit, Mich.) and 0.125% Agarose 1600 (Wako Pure Chemical Industries, Ltd., Osaka) in ES medium supplemented with 10% FBS. The number of cells inoculated into each dish was 1×10^6 . Ouabain had been added in a 2 mM concentration to the agar-agarose layers on the plates. Colony-forming ability was measured as follows. The cells, which had been cultured for additional 3 days for expression, were diluted with fresh ES medium to give a final density of 500 cells/ml. Two hundred μ l of the cell suspension was inoculated onto the surface of agar-agarose plate that did not contain ouabain. The plates were cultured for 10 days, and the colonies formed were counted.

ED₅₀ value refers to the concentration of drug necessary to inhibit the growth rate of cells by 50% of the control, as determined by the procedure described before¹⁷.

REFERENCES

1. This paper constitutes part 91 of 'Nucleosides and Nucleotides'; part 90: Yoshimura, Y., Matsuda, A. and Ueda, T. (1990) *Chem. Pharm. Bull.* in press.
2. Freese, E. (1959) *J. Mol. Biol.* **1**, 87–105.
3. Popowska, E. and Janion, C. (1975) *Nucl. Acids Res.* **2**, 1143–1151.
4. Popowska, E. and Janion, C. (1984) *Biochem. Biophys. Res. Comm.* **56**, 459–466.
5. Janion, C. (1978) *Mutation Res.* **56**, 225–234.
6. Negishi, K., Harada, C., Ohara, Y., Oohara, K., Nitta, N. and Hayatsu, H. (1983) *Nucl. Acids Res.* **11**, 5224–5233.
7. Chu, B.C.F., Brown, D.M. and Burdon, M.G. (1974) *Mutation Res.* **23**, 267–273.
8. Ames, B.N., McCann, J. and Yamasaki, E. (1975) *Mutation Res.* **31**, 347–364.
9. Matsuda, A., Satoh, K., Tanaka, H. and Miyasaka, T. (1984) *Synthesis*, 963–965.
10. Matsuda, A., Ueda, T., Ohara, Y., Satake, H., Negishi, K., Wataya, A. and Hayatsu, H. (1986) *Nucl. Acids Res., Symp. Ser.* **17**, 141–143.
11. Matsuda, A. and Ueda, T. (1987) *Nucleosides & Nucleotides*, **6**, 85–94.
12. Marumoto, R., Yoshioka, Y., Miyashita, O., Shima, S., Imai, K., Kawazoe, K. and Honjo, M. (1985) *Chem. Pharm. Bull.* **23**, 759–774.
13. Markiewicz, W.T. (1979) *J. Chem. Res. Synop.* 24–?
14. Barton, D.H.R. and Subramanian, R. (1977) *J. Chem. Soc., Perkin Trans. 1*, 1718–?
15. Takahashi, M., Nishizawa, M., Negishi, K., Hanaoka, F., Yamada, M. and Hayatsu, H. (1988) *Mol. Cell Biol.* **8**, 347–352.
16. Yahagi, T., Nagao, M., Seino, Y., Matsushima, T., Sugimura, T. and Okada, M. (1977) *Mutation Res.* **48**, 121–129.
17. Yoshioka, A., Tanaka, S., Hiraoka, O., Koyama, Y., Hirota, Y., Ayusawa, D., Seno, T., Garrett, C. and Wataya, Y. (1987) *J. Biol. Chem.* **262**, 8235–8241.